Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bio-Rad Laboratories (FRA:BUWA) Forward PE Ratio Explanation
The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.
Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .
Bio-Rad Laboratories Forward PE Ratio Related Terms
Bio-Rad Laboratories Forward PE Ratio Historical Data
* Premium members only.
The historical data trend for Bio-Rad Laboratories's Forward PE Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bio-Rad Laboratories Forward PE Ratio Chart
Bio-Rad Laboratories Annual Data
Trend
2017-12
2020-12
2021-12
2022-12
2023-12
2024-12
2025-12
Forward PE Ratio
43.86
48.78
48.08
27.47
27.55
29.14
28.83
Bio-Rad Laboratories Quarterly Data
2017-03
2017-06
2017-09
2017-12
2018-03
2018-06
2018-09
2020-12
2021-06
2021-09
2021-12
2022-03
2022-06
2022-09
2022-12
2023-03
2023-06
2023-09
2023-12
2024-03
2024-06
2024-09
2024-12
2025-03
2025-06
2025-09
2025-12
2026-03
Forward PE Ratio
56.50
63.29
49.26
43.86
41.32
46.73
41.49
48.78
48.78
55.87
48.08
36.90
40.32
27.62
27.47
29.50
26.11
24.51
27.55
31.35
24.94
29.59
29.14
24.56
27.29
26.06
28.83
26.53
FRA:BUWA vs GKOS, BRKR, GMED: Forward PE Ratio Comparison
For the Medical Devices subindustry, Bio-Rad Laboratories's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bio-Rad Laboratories Forward PE Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Bio-Rad Laboratories's Forward PE Ratio distribution charts can be found below:
* The bar in red indicates where Bio-Rad Laboratories's Forward PE Ratio falls into.
It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.
Bio-Rad Laboratories (FRA:BUWA) has a Forward PE Ratio of 35.42 as of Jul. 28, 2026. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Bio-Rad Laboratories and its competitors. According to the industry distribution chart, Bio-Rad Laboratories ranks #309 out of 390 companies in the Medical Devices & Instruments industry, placing it in the top 79.2%.
Is Bio-Rad Laboratories' Forward PE Ratio too high?
Bio-Rad Laboratories' current Forward PE Ratio is 35.42. The Medical Devices & Instruments industry median Forward PE Ratio is 18.96. Bio-Rad Laboratories' value of 35.42 is 86.9% above this industry median. Based on the distribution chart, Bio-Rad Laboratories ranks #309 out of 390 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Bio-Rad Laboratories has a GF Score™ of 72/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Bio-Rad Laboratories' Forward PE Ratio compare to GKOS and BRKR?
According to the Medical Devices & Instruments industry distribution chart, Bio-Rad Laboratories ranks #309 out of 390 companies for Forward PE Ratio. This places Bio-Rad Laboratories in the lower half of its industry. The industry median Forward PE Ratio is 18.96. Bio-Rad Laboratories' value of 35.42 is 86.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward PE Ratio for a Medical Devices & Instruments company?
The median Forward PE Ratio among Medical Devices & Instruments companies is 18.96, based on 390 companies in the industry. Companies in the top quartile (top 25%) have a Forward PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Forward PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bio-Rad Laboratories's current Forward PE Ratio of 35.42 is 86.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward PE Ratio mean?
A high Forward PE Ratio can signal that a stock is expensive relative to its fundamentals. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Bio-Rad Laboratories and its competitors. For the Medical Devices & Instruments industry, the median Forward PE Ratio is 18.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bio-Rad Laboratories's current Forward PE Ratio is 35.42. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bio-Rad Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Bio-Rad Laboratories (FRA:BUWA) is currently considered Fairly Valued. The stock's GF Value™ is €272.51, compared to a current price of €278.00 — trading 2% above its estimated fair value. The current Forward PE Ratio is 35.42 and 86.9% above the Medical Devices & Instruments industry median of 18.96. Bio-Rad Laboratories' overall GF Score™ is 72/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward PE Ratio calculated?
Forward PE Ratio is calculated from a company's financial statements. For Bio-Rad Laboratories (FRA:BUWA), the current Forward PE Ratio is 35.42 as of Jul. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bio-Rad Laboratories (FRA:BUWA) Overvalued in 2026?
Based on GuruFocus' analysis, Bio-Rad Laboratories stock appears to be overvalued.
The current stock price of €278.00 is trading 2% above its estimated GF Value™ of €272.51.
GuruFocus considers Bio-Rad Laboratories to be Fairly Valued.
Key valuation signals for FRA:BUWA:
Forward PE Ratio: 35.42
GF Value™: €272.51 vs. price of €278.00 (2% above fair value)
Industry Position: 86.9% above the Medical Devices & Instruments median (#309 of 390)
No single metric tells the full story. See the FRA:BUWA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.
72GF Score
Get the complete analysis for FRA:BUWA
Forward PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:BUWA has been successfully added to your 
